Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

T. Christian H Mix, Robert M. Brenner, Mark E. Cooper, Dick De Zeeuw, Peter Ivanovich, Andrew S. Levey, Janet B. McGill, John J V McMurray, Patrick S. Parfrey, Hans Henrik Parving, Brian J G Pereira, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Catherine Stehman-Breen, Robert D. Toto, Marc A. Pfeffer